Form 8-K May 14, 2013	
UNITED STATES	
SECURITIES AND EXCHANGE COMMISSION	
WASHINGTON, D.C. 20549	
FORM 8-K	
CURRENT REPORT	
Pursuant to Section 13 or 15(d) of the	
Securities Exchange Act of 1934	
Date of report (Date of earliest event reported): May 13, 2013 TG Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter)	
Delaware 001-32639 (State or Other Jurisdiction (Commission File Number) of Incorporation)	36-3898269 (IRS Employer Identification No.)

787 Seventh Ave, 48th Floor

New York, New York 10019

(Address of Principal Executive Offices)

(212) 554-4484

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- "Written communications pursuant to Rule 425 under the Securities Act.
- "Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- "Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Item 2.02. Results of Operations and Financial Condition.

On May 13, 2013, TG Therapeutics, Inc. ("TG" or the "Company") issued a press release announcing results of operations for the first quarter ended March 31, 2013. TG also announced that on Tuesday, May 14, 2013 at 8:30am EST, TG would host an investor conference call during which the Company would provide a brief financial overview of its first quarter financial results and a business outlook for the remainder of 2013. A copy of such press release is being furnished as Exhibit 99.1.

Item 9.01 Financial Statements And Exhibits.

(d) Exhibits.

99.1 Press release issued by TG Therapeutics, Inc., dated May 13, 2013.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics, Inc.

(Registrant)

Date: May 14, 2013 By: /s/ Sean A. Power

Sean A. Power

Chief Financial Officer

-3-

INDEX TO EXHIBITS

Exhibit Number Description

99.1 Press release issued by TG Therapeutics, Inc., dated May 13, 2013.

-4-